Answers are grounded in this paper and cite their sources.
Findings report the efficacy and safety of RP1 with nivolumab in non-melanoma skin cancer, suggesting potential improved outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Schadendorf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: